Latest & greatest articles for levothyroxine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on levothyroxine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on levothyroxine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for levothyroxine

21. Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt Full Text available with Trip Pro

Adding carbimazole to levothyroxine increases triiodothyronine and improves outcome in patients with primary hypothyroidism: a preliminary study from Egypt Many hypothyroid patients are not tolerant and not satisfied with levothyroxine (LT4). Older studies used large doses of both carbimazole and LT4 for Hashimoto's thyroiditis (HT), because Graves' disease (GD) and HT were considered as very closely related syndromes produced by thyroid autoimmunity.The aim of the study was to determine

2017 Electronic physician

22. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Questions for GPs The BTA is aware that some health authorities are advising GPs to switch patients on Liothyronine (L-T3) to Levothyroxine (L-T4). Whilst we appreciate the commercial imperative to cut prescription costs, like you, our first concern is that in all cases the clinical needs of the patient should come before financial considerations. This frequently asked questions (FAQS) sheet has been produced for GPs who (...) of avoiding under-replacement or over- replacement. The final L-T4 requirement is likely to be around 1.6mcg/kg. Any information about previous L-T4 dosage that achieved a normal serum TSH will be a Switching your patient from Liothyronine (L-T3) to Levothyroxine (L-T4)? Answering GP’s frequently asked questions useful guide. Gradual reduction of L-T3 starting at the same time as introducing or increasing L-T4 may be a preferable alternative. Careful monitoring of the patient by an endocrinologist during

2017 British Thyroid Association

23. Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists

Switching from Liothyronine (LT-3) to Levothyroxine (LT-4)? Information for Endocrinologists DECEMBER 2016 BRITISH THYROID ASSOCIATION EXECUTIVE COMMITTEE INFORMATION FOR MEMBERS ON PRESCRIBING LIOTHYRONINE (L-T3) The BTA Executive Committee have been made aware of recent difficulties encountered by patients in obtaining Liothyronine (L-T3). In some instances, patients who have long been established on L-T3 have had their treatment abruptly withdrawn and some clinicians have received requests (...) from local health authorities to switch patients from L-T3 to levothyroxine (L-T4). We are concerned that these actions are driven by cost considerations rather than clinical need and that the BTA position statement on the management of hypothyroidism is being inappropriately cited to support this requests. The BTA does not support the sudden withdrawal of L-T3 therapy and this practice does not in any way reflect our position statement. In this document we highlight current problems with L-T3

2017 British Thyroid Association

24. The impact of levothyroxine therapy in pregnant women with subclinical hypothyroidism on obstetrical and childhood outcomes: systematic review and meta-analysis of randomized controlled trials

The impact of levothyroxine therapy in pregnant women with subclinical hypothyroidism on obstetrical and childhood outcomes: systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2017 PROSPERO

25. Effect of levothyroxine treatment on chronic urticaria in euthyroid patients with thyroid autoantibodies

Effect of levothyroxine treatment on chronic urticaria in euthyroid patients with thyroid autoantibodies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

26. Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children

Randomised controlled trial: Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children Second trimester levothyroxine treatment for subclinical hypothyroidism or hypothyroxinaemia of pregnancy does not improve cognitive outcomes of children | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your (...) browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Second trimester levothyroxine treatment for subclinical

2017 Evidence-Based Medicine

27. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Full Text available with Trip Pro

Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. To compare the effects of a unique fixed combination levothyroxine/liothyronine (LT4/LT3) therapy in patients with primary hypothyroidism.This is a randomized, double-blind, crossover study. Adults with primary hypothyroidism (n = 32, age 42.6 ± 13.3, 30 females) on stable doses of LT4 for ≥ 6 months (125 or 150 μg/day) were randomized to continue LT4 treatment (G1) or to start LT4/LT3

2016 Archives of endocrinology and metabolism Controlled trial quality: uncertain

28. A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism. (Abstract)

A Systematic Review of Clinical Practice Guidelines' Recommendations on Levothyroxine Therapy Alone versus Combination Therapy (LT4 plus LT3) for Hypothyroidism. Patients with hypothyroidism are increasingly enquiring about the benefit of using combination therapy of levothyroxine (LT4) and liothyronine (LT3) as a potential treatment for hypothyroidism. Combination therapy, however, remains controversial. The purpose of this study was to systematically review available hypothyroidism treatment

2015 Clinical and investigative medicine. Médecine clinique et experimentale

29. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with diagnosed primary hypothyroidism

Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with diagnosed primary hypothyroidism Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2015 PROSPERO

30. Levothyroxine or minimally invasive therapies for benign thyroid nodules. (Abstract)

Levothyroxine or minimally invasive therapies for benign thyroid nodules. Thyroid nodules (TN) are common in the adult population. Some physicians use suppressive levothyroxine (LT4) therapy to achieve a reduction in the number and volume of TN. In addition, minimally invasive treatments, such as percutaneous ethanol injection (PEI) sclerotherapy, laser photocoagulation (LP), and microwave (MW), radiofrequency (RF) and high-intensity focused ultrasound (HIFU) ablation, have been proposed

2014 Cochrane

31. Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation

Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Teva levothyroxine 100 microgram tablets: suspension of marketing authorisation Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. Published 11 (...) December 2014 From: Therapeutic area: This article has been superseded. Please see updated information on the , October 2016. Article date: March 2012 Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing

2012 MHRA Drug Safety Update

32. Levothyroxine dose and risk of fractures in older adults: nested case-control study. Full Text available with Trip Pro

Levothyroxine dose and risk of fractures in older adults: nested case-control study. To quantify the effect of levothyroxine dose on risk of fractures in older adults.Nested case-control study.Population based health databases, Ontario, Canada.Adults aged 70 or more prescribed levothyroxine between 1 April 2002 and 31 March 2007 and followed for fractures until 31 March 2008. Cases were cohort members admitted to hospital for any fracture, matched with up to five controls from within the cohort (...) who had not yet had a fracture.Primary outcome was fracture (wrist or forearm, shoulder or upper arm, thoracic spine, lumbar spine and pelvis, hip or femur, or lower leg or ankle) in relation to levothyroxine use (current, recent past, remote). Risk among current users was compared between those prescribed high, medium, and low cumulative levothyroxine doses in the year before fracture.Of 213,511 prevalent levothyroxine users identified, 22,236 (10.4%) experienced a fracture over a mean 3.8 years

2011 BMJ

33. Levothyroxine Sodium for Injection

Levothyroxine Sodium for Injection Drug Approval Package: Levothyroxine Sodium NDA #202231 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Levothyroxine Sodium for Injection, 100 mcg, 200 mcg, and 500 mcg vials Company: APP Pharmaceuticals, LLC Application No.: 202231 Approval Date: 06/24/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

34. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. Full Text available with Trip Pro

Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. Thyroidal production of triiodothyronine (T3) is absent in athyreotic patients, leading to the suggestion that T3 deficiency may be unavoidable during levothyroxine (LT4) therapy. However, trials evaluating therapy with combined LT4 and T3 have failed to demonstrate any consistent advantage of combination therapy.To determine whether T3 levels in patients treated with LT4 therapy were truly lower than in the same

2008 JAMA

35. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. (Abstract)

Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we attempted (...) to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration at preconception values

2004 NEJM

36. The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature

The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

37. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Full Text available with Trip Pro

Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. Standard therapy for patients with primary hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to triiodothyronine, the active form of thyroid hormone. Within the lay population and in some medical communities, there is a perception that adding synthetic triiodothyronine, or liothyronine, to levothyroxine improves (...) the symptoms of hypothyroidism despite insufficient evidence to support this practice.To evaluate the benefits of treating primary hypothyroidism with levothyroxine plus liothyronine combination therapy vs levothyroxine monotherapy.Randomized, double-blind, placebo-controlled trial conducted from May 2000 to February 2002 at a military treatment facility that serves active duty and retired military personnel and their family members. The trial included a total of 46 patients aged 24 to 65 years

2003 JAMA Controlled trial quality: predicted high

38. Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review

Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Starting dose of levothyroxine for the treatment of congenital hypothyroidism: a systematic review Hrytsiuk I, Gilbert R, Logan S, Pindoria S, Brook C G Authors' objectives To determine the effect of levothyroxine sodium starting dose on cognitive development, growth or behaviour in children (...) of levothyroxine. Participants included in the review Children with congenital hypothyroidism, as identified by neonatal screening, whose global or cognitive development had been assessed using a population-standardised measure. The children included in the review were aged between 1 and 14 years. Outcomes assessed in the review First, the authors compared standardised doses of levothyroxine treatment with the mean standardised development scores in cohorts with different starting doses of levothyroxine

2002 DARE.

39. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. (Abstract)

Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. To compare relative bioavailability of Synthroid, Levoxine (Levoxine has been renamed Levoxyl), and 2 generic levothyroxine sodium preparations.Single-blind (primary investigators blinded), randomized, 4-way crossover trial.Ambulatory care.Twenty-two women with hypothyroidism who were clinically and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg.All patients received (...) each of the 4 levothyroxine products for 6-week periods in the same dosage as their prestudy regimen with no washout period. The order of the drug sequences was randomly determined before study initiation.Area under the curve, time to peak serum concentrations, and peak serum concentrations of thyroxine, triiodothyronine, and free thyroxine index for all 4 products.All data analyses were completed prior to unblinding of the product codes. No significant differences between the 4 products were found

1997 JAMA Controlled trial quality: uncertain

40. Effects of restricting levothyroxine dosage strength availability

Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Effects of restricting levothyroxine dosage strength availability Ain K B, Pucino F, Csako G, Wesley R A, Drass J A, Clark C, Ketteridge P, Crawford K, Banks S M, Dorworth T E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Prescribing restricted versus nonrestricted dosage strength of levothyroxine to patients requiring thyroid hormone replacement or suppression of thyrotropin (TSH). The nonrestricted use of levothyroxine consisted of tablets containing 25, 50, 75, 100, 112, 125, 150, 175, 200, and 300 micrograms, while in the restricted-use, only five dosage strengths (25, 50, 100, 125, 150

1996 NHS Economic Evaluation Database.